Abstract: Pseudomonas spp. and Klebsiella pneumoniae are common causes of serious health care associated infections (HCAIs) worldwide. The treatment options for infections caused by multi-drug resistant (MDR) organisms are limited to tigecycline and carbapenems. A total of 172 isolates of multi-drug resistant Pseudomonas spp and extended-spectrum β-(ESBL) producing Klebsiella pneumoniae isolated from clinical specimens at the Bugando Medical Centre were tested for their in vitro susceptibility to piperacillin-tazobactam 100/10μg using disc diffusion test as recommended by Clinical Laboratory Standard Institute (CLSI). Out of 59 multi-drug resistant Pseudomonas spp, 54 (92.0%) were susceptible to piperacillin-tazobactam while of 113 ESBL producing Klebsiella pneumoniae, 55 (48.7%) were susceptible to piperacillin-tazobactam 100/10μg. Also, 20 (34.0%) of the Pseudomonas spp were both ESBL producers and susceptible to piperacillin-tazobactam 100/10μg. A significant proportion of Pseudomonas spp isolates from clinical specimens in our setting are susceptible to piperacillin/tazobactam. This study shows that piperacillin-tazobactam offer a better option to clinicians for the treatment of health care associated infections due to Pseudomonas spp. and ESBL producing Klebsiella pneumoniae in our setting and other health facilities where these organisms are of significance.
Pseudomonas aeruginosa and Klebsiella pneumoniae are bacteria commonly associated with serious infections in hospitalized patients worldwide. Treatment of infections caused by these bacteria is a challenge as they possess multiple resistance mechanisms including β-lactamases production, efflux pumps and impermeable outer membrane (Livermore, 2002) . Despite the improved antibiotic therapy, infections due to multi-drug resistant Pseudomonas aeruginosa and Klebsiella pneumoniae are still associated with increased morbidity and mortality in health care associated settings (Micek et al., 2005) . Therapeutic options of these pathogens are limited to carbapenem and tigecycline which are too expensive and most often unavailable in developing countries. This study was conducted to determine in vitro susceptibility pattern of multi-drug resistant Pseudomonas aeruginosa and Klebsiella pneumoniae to piperacillin/tazobactam, the antibiotic that has been introduced to the market in Tanzania recently. The information generated here is crucial to clinicians so that they can make informed decision when they are prescribing antibiotics to treat these multi-drug resistant organisms.
This was a laboratory based study conducted at Bugando Medical Centre (BMC) in Mwanza, Tanzania. BMC is a 1,000 bed capacity referral and teaching hospital serving a population of about 13 million people in the Lake Victoria zone of Tanzania. A total of 172 multi-drug resistant Klebsiella pneumoniae and Pseudomonas aeruginosa from clinical specimens were involved in the study. These isolates were identified as described previously (Mshana et al., 2009) and ESBL productions were confirmed using disc approximation test method. Susceptibility pattern to piperacillin-tazobactam 100/10μg (Oxoid, UK) was done using disc diffusion method as recommended by CLSI. Briefly, colonies from overnight pure culture were suspended in sterile normal saline to 0.5 McFarland and inoculated on Muller Hinton agar (Oxoid, UK). Using sterile forceps piperacillin-tazobactam 100/10μg discs was placed on the media and plates incubated at 37 o C for 18 hours. Interpretation was done according to Clinical Laboratory Standard Institute guidelines whereby the diameter of >18mm was recorded as sensitive and ≤18mm was recorded as resistance for Pseudomonas aeruginosa while for Klebsiella pneumoniae the diameter of ≥21mm was considered as sensitive, 18-20mm as intermediate while ≤17mm as resistance (Figure 1 ). We evaluated the antimicrobial susceptibility pattern of 133 ESBL producing [Pseudomonas aeruginosa (20) and Klebsiella pneumoniae (113)] and 39 multi-drug resistant non-ESBL producing Pseudomonas spp. Majority of these isolates were from blood (76), while others were from pus swabs (74), urine (20), and aspirate (2) ( Table 1) . Out of 172 multi-drug resistant isolates in the study 113 (65.7%) were Klebsiella pneumoniae whereas among 59 Pseudomonas aeruginosa isolates, 20 (33.9%) were found to be ESBL producers. Carbapenem has been preferred as the drug of choice for treatment of multi drug resistant bacteria (Paterson et al., 2001) , this class of antibiotics are unavailable and too expensive to most of Tanzanians. In Tanzania high mortality has been observed with infections associated with ESBL producing gram negative bacteria (Kayange et al., 2010) . In our setting, high prevalence of health care associated infections due to ESBL producing Klebsiella pneumoniae have been observed in surgical wards and neonatal units (Mshana et al., 2013) . Pseudomonas spp also have been found to be common causes of wound infections in our setting (Mbunda et al., 2012) . In the present study majority of Pseudomonas spp were from wound infections out of which 33.9% of them were found to produce ESBL. Compared to previous findings (Mshana et al., 2009) there is increase in ESBL producing Pseudomonas spp in our setting, however higher rates than this have been reported elsewhere (Begum et al., 2013) . (Pathmanathan et al., 2009) . Our results and other similar studies suggest that piperacillin-tazobactam may be good available alternative antibiotics to carbapenems for infections due Pseudomonas spp and to about 50% of ESBL producing Klebsiella pneumoniae in areas where in vitro susceptibility data is not availability (Ejaz et al., 2011; Seni et al., 2013) . In general, the sensitivity rates of multi-resistant Pseudomonas aeruginosa and Klebsiella pneumoniae to Piperacillintazobactam in our setting is higher than that of cefepime (Mshana et al., 2011) A significant proportion of Pseudomonas aeruginosa isolates in our setting are susceptible to piperacillin-tazobactam. It is essential to understand local susceptibility patterns in order to optimize treatment of infectious diseases; hence, more of these studies need to be carried out. This study shows that piperacillin-tazobactam in the availability of susceptibility results offer a better option to clinicians for the treatment of health care associated infections due to Pseudomonas spp. and ESBL producing Klebsiella pneumoniae where these organisms are of public health significance.
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